At present, they said, the company has formed a multi-target, multi-mechanism and multi-indication CAR-iNK pipeline, and three products have entered clinical verification. The development of the iT pipeline is also underway, with innovations focused on how to enhance in vivo expansion and persistence. Leading products are about to enter preclinical studies. On the basis of its experience, is it also exploring in vivo CAR technology.
Market Data 
Markets 
AI
